Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study
Conclusion Treatment with sorafenib plus ifosfamide achieved a significant clinical benefit with an acceptable safety profile in patients with advanced soft tissue sarcoma resistant to anthracyclines, which warrants a more detailed study in randomized clinical trials.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Clinical Trials | Drugs & Pharmacology | Investigational New Drugs | Sarcomas | Soft Tissue Sarcoma | Spain Health | Study | Toxicology